Marshall Wace’s Axsome Therapeutics AXSM Stock Holding History

Marshall Wace’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$23.9M	Sell	141,236 -179,332	-56%	-$31M	0.02%	635
2025 Q4	$58.5M	Sell	320,568 -57,456	-15%	-$8.02M	0.05%	308
2025 Q3	$45.9M	Buy	378,024 +321,308	+567%	+$36.2M	0.05%	344
2025 Q2	$5.92M	Sell	56,716 -11,980	-17%	-$1.27M	0.01%	1063
2025 Q1	$8.01M	Sell	68,696 -58,401	-46%	-$6.65M	0.01%	858
2024 Q4	$10.8M	Buy	+127,097	New	+$11.7M	0.01%	770
2023 Q4	–	Sell	-59,248	Closed	-$4.14M	–	2177
2023 Q3	$4.14M	Sell	59,248 -132,263	-69%	-$9.89M	0.01%	941
2023 Q2	$13.8M	Buy	191,511 +184,390	+2,589%	+$13.6M	0.03%	612
2023 Q1	$439K	Buy	+7,121	New	+$468K	﹤0.01%	2154
2022 Q3	–	Sell	-27,393	Closed	-$1.05M	–	3330
2022 Q2	$1.05M	Buy	+27,393	New	+$866K	﹤0.01%	2413
2021 Q2	–	Sell	-23,374	Closed	-$1.32M	–	2644
2021 Q1	$1.32M	Buy	+23,374	New	+$1.64M	0.01%	1521
2020 Q2	–	Sell	-79,454	Closed	-$4.67M	–	1544
2020 Q1	$4.67M	Buy	+79,454	New	+$6.47M	0.05%	401

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's AXSM Position: Q1 2026 in Review

Marshall Wace reduced its Axsome Therapeutics (AXSM) stake by 56% in Q1 2026, selling an estimated $31M and leaving 141,236 shares worth $23.9M. The position accounts for 0.02% of the portfolio, ranked #635.

Marshall Wace first reported a position in AXSM in Q1 2020 and has held it in 12 quarters since. The position peaked at $58.5M in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Marshall Wace held 141,236 shares of Axsome Therapeutics worth $23.9M as of Q1 2026.
Marshall Wace sold 179,332 Axsome Therapeutics shares in Q1 2026, an estimated $31M.
Axsome Therapeutics made up 0.02% of Marshall Wace's portfolio in Q1 2026, its #635 holding.
Marshall Wace first reported a position in Axsome Therapeutics in Q1 2020 and has held it in 12 quarters since.
Marshall Wace's Axsome Therapeutics position peaked at $58.5M in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.